Nasdaq:US$12.13 (-0.47) | HKEX:HK$18.84 (-0.56) | AIM:£2.00 (+0)
Search
News & Press Releases
1234567
8
found Documents: 362
Announcements & Press Releases, Oncology / Immunology | 20 Aug 2007

Chi-Med Announces Drug Discovery and Development Agreement with Eli Lilly and Company
a070820
Announcements & Press Releases, Group | 9 Aug 2007

Interim Results for the Six Months Ended 30 June 2007
a070809
Announcements & Press Releases, Oncology / Immunology | 2 Jul 2007

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
a070702
Announcements & Press Releases, Oncology / Immunology | 18 Jun 2007

Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility
a070618
Announcements & Press Releases, Oncology / Immunology | 23 May 2007

Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China
a070523
Announcements & Press Releases, Group | 21 Mar 2007

Preliminary Results for the year ended 31 December 2006
a070321
Announcements & Press Releases, Other Ventures | 17 Jan 2007

Related party transaction Chi-Med formalises China Sales and Distribution Arrangements
a070117
Announcements & Press Releases, Oncology / Immunology | 20 Nov 2006

Chi-Med and Merck KGaA Start Collaboration to Discover Novel Small Molecule Anti-Cancer Drugs
a061120
Announcements & Press Releases, Oncology / Immunology | 6 Nov 2006

Development Agreement with Procter & Gamble for the Discovery and Development of New Active Ingredients for Beauty Products
a061106
Announcements & Press Releases, Group | 9 Aug 2006

Financial Results for the Six Months Ended 30 June 2006
p060809
Announcements & Press Releases, Group | 17 Jul 2006

Trading Update
a060717
Announcements & Press Releases, Oncology / Immunology | 4 Jul 2006

Chi-Med plans to broaden clinical trials of its leading oncology drug candidate
a060704
1234567
8